Effect of anti-vascular endothelial growth factor (VEGF) drugs in chronic central serous chorioretinopathy (CSC)
Not Applicable
- Conditions
- chronic central serous chorioretinopathy
- Registration Number
- JPRN-UMIN000014110
- Lead Sponsor
- Kansai medical university takii hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
none
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Ratio of patients with improved/maintained best-corrected visual acuity (BCVA) at month 1,3,6,12 2) Ratio of patients with improved central retinal thickness (CRT) at month 1,3,6,12
- Secondary Outcome Measures
Name Time Method Change of BCVA, CRT etc.